Setting the stage for increasing diversity in congenital cardiology

Hagdorn, Quint A. J.; Berger, Rolf M. F.

Published in: Cardiology in the young

DOI: 10.1017/S1047951119003081

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date: 2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Setting the stage for increasing diversity in congenital cardiology: let’s celebrate the 75th anniversary of the Blalock–Thomas–Taussig shunt

Quint A. J. Hagdorn and Rolf M. F. Berger

Center for Congenital Heart Diseases, Department of Pediatric Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Dear editor,

Recently, the Editors of the Lancet Group announced a laudable “Diversity Pledge” to increase gender equity, diversity, and inclusion in research. They also encouraged members of the scientific community to contribute to this initiative. This year’s 75th anniversary of a landmark medical achievement provides the perfect opportunity for the congenital cardiology community to follow their lead. In 1944, the first surgical creation of a systemic-to-pulmonary shunt was successfully performed in a blue baby, as a surgical palliative treatment for tetralogy of Fallot. Helen Taussig, a White paediatric cardiologist at John Hopkins Hospital, realised that infants with severe cyanosis would benefit from an assured pulmonary blood flow. She therefore challenged Alfred Blalock, head of surgery at John Hopkins, and also White, to surgically create a similar type of shunt. This procedure, which became known as the Blalock–Taussig shunt, has prolonged thousands of lives and spearheaded the development of heart surgery for CHD. However, it is nowadays generally acknowledged that a third person played a key role in leading this life-saving surgical procedure into clinical practice: Vivien Thomas, Blalock’s African-American laboratory assistant. He first developed the technique in a myriad of laboratory dogs, then adapted the instruments for human use, and eventually coached Blalock through the first operations on infants.

In those times of racial segregation, Thomas did not share in the fame and recognition that Blalock and Taussig received after publishing this landmark achievement. As a Black, non-degreed laboratory assistant Thomas was initially not included in any form of publicity nor acknowledged for his undisputed experimental and clinical contributions. Decades later, attempts were made to alleviate this inequity: Thomas was awarded an honorary Doctor’s degree by Johns Hopkins University. Yet, despite earlier suggestions to rename the Blalock–Taussig shunt into the Blalock–Thomas–Taussig shunt, trivial arguments as “it would be impractical to change the name of the shunt” have apparently precluded to provide Vivien Thomas the deserved honour of having the shunt named after him.

Let us now put this Diversity Pledge into practice, and rename the Blalock–Taussig shunt to the Blalock–Thomas–Taussig shunt, as a shining example to support and encourage diversity. The Blalock–Thomas–Taussig shunt would not only rightfully honour Vivien Thomas but also repeatedly remind us to value intellectual contribution instead of race, gender, socio-economic status, or other factors that may influence authorship until today. Especially in paediatrics and adolescent medicine, such statements are encouraged and highly needed.

Financial Support. No funding source had any role in the writing of this manuscript.

Conflicts of Interest. The University Medical Center Groningen has received fees for consultancy activities of R. Berger for Actelion and Lilly outside the content of this manuscript. Q. Hagdorn declares no competing interests.

References